Effects of oral hypoglycemic agents on platelet function

Journal of Diabetes and its Complications

Volumn 29, Issue 6, 2015, Pages 846-851

  Papazafiropoulou, Athanasia ^a,b   Papanas, Nikolaos ^c   Pappas, Stavros ^a   Maltezos, Efstratios ^c   Mikhailidis, Dimitri P ^d  

^a GENERAL HOSPITAL OF NIKEA   (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Diabetes mellitus; Glitazones; Incretins; Metformin; Platelets; Sulfonylureas

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SITAGLIPTIN; SULFONYLUREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR RISK; HUMAN; HYPOGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84942818660     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.04.005     Document Type: Review

References (92)

1. Akbiyik, F., Ray, D. M., Gettings, K. F., Blumberg, N., Francis, C. W., & Phipps, R. P. (2004). Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood, 104, 1361-1368.
2. Angiolillo, D. J. (2009). Antiplatelet therapy in diabetes: Efficacy and limitations of current treatment strategies and future directions. Diabetes Care, 32, 531-540.
3. Arfors, K. E., Bergqvist, D., & Tangen, O. (1980). Effects of gliclazide-a new antidiabetic agent-on blood platelet function in vitro and in vivo. Upsala Journal of Medical Sciences, 85, 74-83.
4. Barradas, M. A., Gill, D. S., Fonseca, V. A., Mikhailidis, D. P., & Dandona, P. (1988). Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. European Journal of Clinical Investigation, 18, 399-404.
5. Barradas, M. A., Mikhailidis, D. P., & Dandona, P. (1987). The effect of non-esterified fatty acids on vascular ADP-degrading enzyme activity. Diabetes Research and Clinical Practice, 3, 9-19.
6. Beckman, J. A., Creager, M. A., & Libby, P. (2002). Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA, 287, 2570-2581.
7. Birnbaum, Y., Ye, Y., Lin, Y., Freeberg, S. Y., Huang, M. H., Perez-Polo, J. R., et al. (2007). Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. Prostaglandins & Other Lipid Mediators, 83, 89-98.
8. Bodary, P. F., Vargas, F. B., King, S. A., Jongeward, K. L., Wickenheiser, K. J., & Eitzman, D. T. (2005). Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. Journal of Thrombosis and Haemostasis, 3, 2149-2153.
9. Borchert, M., Schöndorf, T., Lübben, G., Forst, T., & Pfützner, A. (2007). Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function. Diabetes Technology & Therapeutics, 9, 410-420.
10. Chokesuwattanaskul, W., Yaqub, Y., Suarez, J. A., Simoni, J., Simoni, G., Nugent, K. M., et al. (2010). Effect of pioglitazone on platelet aggregation in a healthy cohort. Cardiology, 116, 253-256.
11. Collier, A., Watson, H. H., Patrick, A. W., Ludlam, C. A., & Clarke, B. F. (1989). Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabète and Métabolisme, 15, 420-425.
12. Cubbon, R. M., Wheatcroft, S. B., Grant, P. J., Gale, C. P., Barth, J. H., Sapsford, R. J., et al. (2007). Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: A comparison of over 3000 patients between 1995 and 2003. European Heart Journal, 28, 540-545.
13. Davì, G., & Patrono, C. (2007). Platelet activation and atherothrombosis. New England Journal of Medicine, 357, 2482-2494.
14. De Bellis, R., Novoa, E., Dol, B., Cazerez, J., Arroyo, G., Balbela, B., et al. (1984). Changes in platelet aggregation caused by glyburide in diabetic patients. Clinical Therapeutics, 6, 335-343.
15. Dolasik, I., Sener, S. Y., Celebi, K.,Aydin, Z.M., Korkmaz, U.,&Canturk, Z. (2013). The effect of metformin onmean platelet volume in diabetic patients. Platelets, 24, 118-121.
16. Engel, S. S., Golm, G. T., Shapiro, D., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2013). Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: A pooled analysis. Cardiovascular Diabetology, 12, 3-14.
17. Ferreira, I. A., Mocking, A. I., Feijge, M. A., Gorter, G., van Haeften, T. W., Heemskerk, J. W., et al. (2006). Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 26, 417-422.
18. Ferreiro, J. L., & Angiolillo, D. J. (2011). Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation, 123, 798-813.
19. Ferroni, P., Basili, S., & Davi, G. (2003). Platelet activation, inflammatory mediators and hypercholesterolemia. Current Vascular Pharmacology, 1, 157-169.
20. Florkowski, C. M., Richardson, M. R., Le Guen, C., Jennings, P. E., O'Donnell, M. J., Jones, A. F., et al. (1988). Effect of gliclazide on thromboxane B2, parameters of haemostasis, fluorescent IgG and lipid peroxides in non-insulin dependent diabetes mellitus. Diabetes Research, 9, 87-90.
21. Formoso, G., De Filippis, E. A., Michetti, N., Di Fulvio, P., Pandolfi, A., Bucciarelli, T., et al. (2008). Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes/Metabolism Research and Reviews, 24, 231-237.
22. Gasparyan, A. Y., Ayvazyan, L., Mikhailidis, D. P., & Kitas, G. D. (2011). Mean platelet volume: A link between thrombosis and inflammation? Current Pharmaceutical Design, 17, 47-58.
23. Gastpar, H.,Weissgerber, P.W., Enzmann, F.,&Zoltobrocki,M. (1982). The inhibition of cancer cell stickiness, amodel for investigation of platelet aggregation inhibitors in vivo. Effect of the sulfonyl urea derivatives, glibenclamide, gliclazide, and HB180, as well as the carboxylic acid derivative, meglitinide. Research in Experimental Medicine, 180, 75-84.
24. Gin, H., Freyburger, G., Boisseau, M., & Aubertin, J. (1989). Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. Diabetes Research and Clinical Practice, 6, 61-67.
25. Gogitidze, Joy N., Hedrington, M. S., Briscoe, V. J., Tate, D. B., Ertl, A. C., & Davis, S. N. (2010). Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care, 33, 1529-1535.
26. Gonçalves, L. H., Silva, M. V., Duarte, R. C., Dusse, L. M., Fernandes, A. P., Bosco, A. A., et al. (2014). Acetylsalicylic acid therapy: Influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels. Clinica Chimica Acta, 429, 76-78.
27. Gregorio, F., Ambrosi, F., Manfrini, S., Velussi, M., Carle, F., Testa, R., et al. (1999). Poorly controlled elderly Type 2 diabetic patients: The effects of increasing sulphonylurea dosages or adding metformin. Diabetic Medicine, 16, 1016-1024.
28. Gupta, A. K., Verma, A. K., Kailashiya, J., Singh, S. K., & Kumar, N. (2012). Sitagliptin: antiplatelet effect in diabetes and healthy volunteers. Platelets, 23, 565-570.
29. Haffner, S. M., Lehto, S., Ronnemaa, T., Pyorala, K., & Laakso, M. (1998). Mortality from coronary heart disease in subjectswith type 2 diabetes and in nondiabetic subjectswith andwithout priormyocardial infarction. New England Journal ofMedicine, 339, 229-234.
30. Harmsze, A. M., Van Werkum, J. W., Moral, F., Ten Berg, J. N., Hackeng, C. M., Klungel, O. H., et al. (2011). Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets, 22, 98-102.
31. Hartley, P. S., Savill, J. S., & Brown, S. B. (2007).Hypoglycaemia predisposes platelets to death by affecting calcium homeostasis and mitochondrial integrity. Platelets, 18, 103-112.
32. Henn, V., Slupsky, J. R., Gräfe, M., Anagnostopoulos, I., Förster, R., Müller-Berghaus, G., et al. (1998). CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 391, 591-594.
33. Hetzel, J., Balletshofer, B., Rittig, K., Walcher, D., Kratzer, W., Hombach, V., et al. (2005). Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 1804-1809.
34. Hutton, R. A., Mikhailidis, D., Dormandy, K. M., & Ginsburg, J. (1979). Platelet aggregation studies during transient hypoglycaemia: A potential method for evaluating platelet function. Journal of Clinical Pathology, 32, 434-438.
35. Ishizuka, T., Itaya, S.,Wada, H., Ishizawa, M., Kimura, M., Kajita, K., et al. (1998). Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes, 47, 1494-1500.
36. Israeli, A., Matzner, Y., Or, R., & Raz, I. (1988). Glibenclamide causing thrombocytopenia and bleeding tendency: Case reports and a review of the literature. Klinische Wochenschrift, 66, 223-224.
37. Jagroop, A., & Mikhailidis, D. P. (2015). Platelets and diabetes: A complex association. Platelets, 26, 267-268.
38. Jennings, P. E., Scott, N. A., Saniabadi, A. R., & Belch, J. J. (1992). Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: Clinical assessment. Metabolism, 41, 36-39.
39. Jeremy, J. Y., Mikhailidis, D. P., & Dandona, P. (1983). Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes, 32, 217-221.
40. Joy, N. G., Tate, D. B., Younk, L. M., & Davis, S. N. (2015). Effects of acute and antecedent hypoglycemia on endothelial function and markers of atherothrombotic balance in healthy man. Diabetes (pii: db141729, Epub ahead of print).
41. Kasono, K., Nishida, J., Tamemoto, H., Fudaka, K., Namai, K., Kajio, H., et al. (2002). Thiazolidinediones increase the number of platelets in immune thrombocytopenic purpura mice via inhibition of phagocytic activity of the reticulo-endothelial system. Life Sciences, 71, 2037-2052.
42. Khanolkar, M. P., Morris, R. H., Thomas, A.W., Bolusani, H., Roberts, A.W., Geen, J., et al. (2008). Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus-an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis, 197, 718-724.
43. King, J. B., Kalk, W. J., Vinik, A. I., Jackson, W. P., Bracher, M., & Jacobs, P. (1977). An evaluation of the effects of some sulphonylureas on platelet function. South African Medical Journal, 51, 124-126.
44. Klaff, L. J., Kernoff, L., Vinik, A. I., Jackson, W. P., & Jacobs, P. (1981). Sulfonylureas and platelet function. American Journal of Medicine, 70, 627-630.
45. Klaff, L. J., Vinik, A. I., Jackson, W. P., Malan, E., Kernoff, L., & Jacobs, P. (1979). Effects of the sulphonylurea drugs gliclazide and glibenclamide on blood glucose control and platelet function. South African Medical Journal, 56, 247-250.
46. Koibuchi, N., Hasegawa, Y., Katayama, T., Toyama, K., Uekawa, K., Sueta, D., et al. (2014). DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovascular Diabetology, 13, 157-168.
47. Konya, H., Hasegawa, Y., Hamaguchi, T., Satani, K., Umehara, A., Katsuno, T., et al. (2010). Effects of gliclazide on platelet aggregation andthe plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. Metabolism, 59, 1294-1299.
48. Larkins, R. G., Jerums, G., Taft, J. L.,Godfrey, H., Smith, I. L., & Martin, T. J. (1988). Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: A two-year controlled study. Diabetes Research and Clinical Practice, 4, 81-87.
49. Li, D., Chen, K., Sinha, N., Zhang, X., Wang, Y., Sinha, A. K., et al. (2005). The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovascular Research, 65, 907-912.
50. Mikhailidis, D. P., Barradas, M. A., Jeremy, J. Y., & Dandona, P. (1989). Effect of alpha aadrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 32, 147-149.
51. Mikhailidis, D. P., Barradas, M. A., Maris, A., Jeremy, J. Y., & Dandona, P. (1985). Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: Pathological implications in vascular disease. Journal of Clinical Pathology, 38, 1166-1171.
52. Mizuno, A., Yano, M., Isobe, J., & Shima, K. (1989). Inhibitory action of gliclazide on platelet functions. Diabetes Research and Clinical Practice, 7, 141-147.
53. Mongan, J., Mieszczanska, H. Z., Smith, B. H., Messing, S. P., Phipps, R. P., & Francis, C. W. (2012). Pioglitazone inhibits platelet function and potentiates the effects of aspirin: A prospective observation study. Thrombosis Research, 129, 760-764.
54. Natarajan, A., Zaman, A.G.,&Marshall, S.M. (2008). Platelet hyperactivity in type 2 diabetes: Role of antiplatelet agents. Diabetes & Vascular Disease Research, 5, 138-144.
55. Ozaki, Y., Yatomi, Y., & Kume, S. (1992). Effects of oral hypoglycaemic agents on platelet functions. Biochemical Pharmacology, 44, 687-691.
56. Pafili, K., & Papanas, N. (2014). Luseogliflozin and other sodium-glucose cotransporter 2 inhibitors: No enemy but time? Expert Opinion on Pharmacotherapy, 16, 453-456.
57. Papanas, N., & Maltezos, E. (2012). Antidiabetic treatment: Though lovers be lost, love shall not. World Journal of Diabetes, 3, 158-160.
58. Papanas, N., & Mikhailidis, D. P. (2014). Mean platelet volume: A predictor of mortality in diabetic and non-diabetic patients with STEMI? Journal of Diabetes and its Complications, 28, 581-582.
59. Park, K. W., Kang, J., Park, J. J., Yang, H. M., Kwon, Y. W., Lee, H. Y., et al. (2013). Thiazolidinedione usage is associated with decreased response to clopidogrel in DM patients. International Journal of Cardiology, 168, 608-610.
60. Paton, R. C., Kernoff, P. B., Wales, J. K., & McNicol, G. P. (1981). Effects of diet and gliclazide on the haemostatic system of non-insulin-dependent diabetics. British Medical Journal (Clinical Research Ed.), 283, 1018-1020.
61. Pfützner, A., Hanefeld, M., Afzal-Dekordi, L., Müller, J., Kleine, I., Fuchs, W., et al. (2009). PIOace-Study: Pioglitazone, but not Ramipril improves thrombocyte function and reduces low grade inflammation in non-diabetic patients with increased cardiovascular risk. Diabetologia, 52, 335-336.
62. Phenekos, C., Siafaka-Kapadai, A., Trapali, M., Botitsi, E., & Mavris, M. (1992). Effect of gliclazide on platelet-activating factor-induced platelet aggregation in patients with non-insulin-dependent diabetes mellitus. Metabolism, 41, 30-32.
63. Qi, R., Ozaki, Y., Satoh, K., Kurota, K., Asazuma, N., Yatomi, Y., et al. (1995). Sulphonylurea agents inhibit platelet aggregation and [Ca2+]i elevation induced by arachidonic acid. Biochemical Pharmacology, 49, 1735-1739.
64. Randriamboavonjy, V., Pistrosch, F., Bölck, B., Schwinger, R. H., Dixit, M., Badenhoop, K., et al. (2008). Platelet sarcoplasmic endoplasmic reticulum Ca2 + -ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone. Circulation, 117, 52-60.
65. Ray, D. M., Spinelli, S. L., O'Brien, J. J., Blumberg, N., & Phipps, R. P. (2006). Platelets as a novel target for PPARgamma ligands: Implications for inflammation, diabetes, and cardiovascular disease. BioDrugs, 20, 231-241.
66. Rubinjoni, Z., Turk, Z., Coce, F., Mustovic, D., Maitre, D., & Skrabalo, Z. (1978). Effect on platelet adhesiveness in diabetics after long-term treatment with a new oral hypoglycaemic agent, gliclazide. Current Medical Research and Opinion, 5, 625-631.
67. Satoh, K., Ozaki, Y., Yatomi, Y., & Kume, S. (1994). Effects of sulfonylurea agents on platelet arachidonic acid metabolism; Study on platelet homogenates. Biochemical Pharmacology, 48, 1053-1055.
68. Schäfer, A., Widder, J., Eigenthaler, M., Bischoff, H., Ertl, G., & Bauersachs, J. (2004). Increased platelet activation in young Zucker rats with impaired glucose tolerance is improved by acarbose. Thrombosis and Haemostasis, 92, 97-103.
69. Schöndorf, T., Musholt, P. B., Hohberg, C., Forst, T., Lehmann, U., Fuchs, W., et al. (2011). The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: Results from the PIOfix study. Journal of Diabetes Science and Technology, 5, 426-432.
70. Shimazu, T., Inami, N., Satoh, D., Kajiura, T., Yamada, K., Iwasaka, T., et al. (2009). Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients. Journal of Thrombosis and Thrombolysis, 28, 429-435.
71. Sidhu, J. S., Cowan, D., & Kaski, J. C. (2003). The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. Journal of the American College of Cardiology, 42, 1757-1763.
72. Sidhu, J. S., Cowan, D., Tooze, J. A., & Kaski, J. C. (2004). Peroxisome proliferatoractivated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. American Heart Journal, 147, e25-31.
73. Siluk, D., Kaliszan, R., Haber, P., Petrusewicz, J., Brzozowski, Z., & Sut, G. (2002). Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia, 45, 1034-1037.
74. Stratmann, B., & Tschoepe, D. (2005). Pathobiology and cell interactions of platelets in diabetes. Diabetes & Vascular Disease Research, 2, 16-23.
75. Stratmann, B., & Tschoepe, D. (2009). Atherogenesis and atherothrombosis-focus on diabetes mellitus. Best Practice & Research. Clinical Endocrinology & Metabolism, 23, 291-303.
76. Suryadevara, S., Ueno, M., Tello-Montoliu, A., Ferreiro, J. L., Desai, B., Rollini, F., et al. (2012). Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. Thrombosis and Haemostasis, 108, 930-936.
77. Svobodová, H., Stulc, T., Kasalová, Z., Dolezalová, R., Marinov, I., Capek, P., et al. (2009). The effect of rosiglitazone on the expression of thrombogenic markers in leukocytes in type 2 diabetes mellitus. Physiological Research, 58, 701-707.
78. Takeda, H., Kishikawa, H., Shinohara, M., Miyata, T., Suzaki, K., Fukushima, H., et al. (1988). Effect of alpha 2-adrenoceptor antagonist on platelet activation during insulin-induced hypoglycaemia in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 31, 657-663.
79. Terawaki, Y., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Takahashi, H., Tanaka, T., et al. (2014). Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovascular Diabetology, 13, 154-162.
80. Ting, H. J., & Khasawneh, F. T. (2010). Glibenclamide: An antidiabetic with in vivo antithrombotic activity. European Journal of Pharmacology, 649, 249-254.
81. Tremoli, E., Ghiselli, G.,Maderna, P., Colli, S., & Sirtori, C. R. (1982). Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits. Atherosclerosis, 41, 53-60.
82. Tushuizen, M., Diamant, M., & Heine, R. (2005). Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Postgraduate Medical Journal, 81, 1-6.
83. Vaidyula, V. R., Boden, G., & Rao, A. K. (2006). Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets, 17, 577-585.
84. Viles-Gonzalez, J. F., Anand, S. X., Valdiviezo, C., Zafar, M. U., Hutter, R., Sanz, J., et al. (2004). Update in atherothrombotic disease. Mount Sinai Journal of Medicine, 71, 197-208.
85. Vinik, A. I., Erbas, T., Park, T. S., Nolan, R., & Pittenger, G. L. (2001). Platelet dysfunction in type 2 diabetes. Diabetes Care, 24, 1476-1485.
86. Violi, F., De Mattia, G. C., Alessandri, C., Perrone, A., & Vezza, E. (1982). The effects of gliclazide on platelet function in patients with diabetes mellitus. Current Medical Research and Opinion, 8, 200-203.
87. Watala, C., Boncler, M., & Gresner, P. (2005). Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacological Reports, 57, 42-58.
88. Waysbort, J., Regitz, G., Chaimowitz, D., Tuval, M., Nakash, I., & Brunner, D. (1988). Effects of glibenclamide on serum lipids, lipoproteins, thromboxane, betathromboglobulin, and prostacyclin in non-insulin-dependent diabetes mellitus. Clinical Therapeutics, 10, 358-371.
89. Yngen, M., Norhammar, A., Hjemdahl, P., & Wallén, N. H. (2006). Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diabetes & Vascular Disease Research, 3, 52-56.
90. Yngen, M., Ostenson, C. G., Hjemdahl, P., & Wallén, N. H. (2006). Meal-induced platelet activation in type 2 diabetes mellitus: Effects of treatment with repaglinide and glibenclamide. Diabetic Medicine, 23, 134-140.
91. Ziegler, O., & Drouin, P. (1991). Hemobiological activity of gliclazide in diabetes mellitus. Diabetes Research and Clinical Practice, 14, S83-S89.
92. Zurro Hernandez, J., & Lavielle, R. (1986). Is sulphonylurea therapy effective long term? A 3-year study with gliclazide. Current Medical Research and Opinion, 10, 351-358.